CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
- PMID: 22917689
- PMCID: PMC3652709
- DOI: 10.1177/1352458512458010
CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
Abstract
Background: Axonal damage is considered a major cause of disability in multiple sclerosis (MS) and may start early in the disease. Specific biomarkers for this process are of great interest.
Objective: To study if cerebrospinal fluid (CSF) biomarkers for axonal damage reflect and predict disease progression already in the earliest stages of the disease, that is, in clinically isolated syndrome (CIS).
Methods: We assessed CSF levels of neurofilament heavy (NFH), neurofilament light (NFL) and N-acetylaspartate (NAA) in 67 patients with CIS and 18 controls with neuropsychiatric diseases of non-inflammatory aetiology (NC). Patients with CIS underwent baseline magnetic resonance imaging (MRI) at 3T, and a follow-up MRI after 1 year was obtained in 28 of them.
Results: Compared with NC, patients with CIS had higher NFH (p=0.05) and NFL (p<0.001) levels. No significant group differences were found for NAA. Patients' NFH levels correlated with physical disability (r=0.304, p<0.05) and with change in brain volume over 1 year of follow-up (r=-0.518, p<0.01) but not with change in T2 lesion load.
Conclusion: Our results confirm increased neurofilament levels already in CIS being related to the level of physical disability. The association of NFH levels with brain volume but not lesion volume changes supports the association of these markers with axonal damage.
Conflict of interest statement
Figures
Similar articles
-
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f. Neurology. 2009. PMID: 19365053
-
Neurofilament light chain level is a weak risk factor for the development of MS.Neurology. 2016 Sep 13;87(11):1076-84. doi: 10.1212/WNL.0000000000003085. Epub 2016 Aug 12. Neurology. 2016. PMID: 27521440 Free PMC article.
-
Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis.Eur J Neurol. 2017 May;24(5):703-712. doi: 10.1111/ene.13274. Epub 2017 Mar 6. Eur J Neurol. 2017. PMID: 28261960
-
Neurofilament light chain in the assessment of patients with multiple sclerosis.Arq Neuropsiquiatr. 2019 Jul 15;77(6):436-441. doi: 10.1590/0004-282X20190060. Arq Neuropsiquiatr. 2019. PMID: 31314847 Review.
-
A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia.Neurodegener Dis. 2007;4(2-3):185-94. doi: 10.1159/000101843. Neurodegener Dis. 2007. PMID: 17596713 Review.
Cited by
-
Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review.Front Mol Neurosci. 2023 Sep 12;16:1210091. doi: 10.3389/fnmol.2023.1210091. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37781097 Free PMC article. Review.
-
Biomarkers in autoimmune diseases of the central nervous system.Front Immunol. 2023 Apr 5;14:1111719. doi: 10.3389/fimmu.2023.1111719. eCollection 2023. Front Immunol. 2023. PMID: 37090723 Free PMC article. Review.
-
Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes.Rev Neurol (Paris). 2023 Mar;179(3):208-217. doi: 10.1016/j.neurol.2022.11.002. Epub 2022 Nov 30. Rev Neurol (Paris). 2023. PMID: 36610823 Free PMC article.
-
Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis.Brain Behav. 2023 Jan;13(1):e2873. doi: 10.1002/brb3.2873. Epub 2022 Dec 27. Brain Behav. 2023. PMID: 36573731 Free PMC article.
-
A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis.J Pers Med. 2022 Aug 31;12(9):1430. doi: 10.3390/jpm12091430. J Pers Med. 2022. PMID: 36143216 Free PMC article. Review.
References
-
- Kuhlmann T, Lingfeld G, Bitsch A, et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202–2212 - PubMed
-
- Wattjes MP, Harzheim M, Lutterbey GG, et al. Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007; 28: 1517–1522 - PubMed
-
- Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48: 893–901 - PubMed
-
- van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747–754 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
